DE60315939D1 - Pharmazeutische zusammensetzung enthaltend ein androgen - Google Patents

Pharmazeutische zusammensetzung enthaltend ein androgen

Info

Publication number
DE60315939D1
DE60315939D1 DE60315939T DE60315939T DE60315939D1 DE 60315939 D1 DE60315939 D1 DE 60315939D1 DE 60315939 T DE60315939 T DE 60315939T DE 60315939 T DE60315939 T DE 60315939T DE 60315939 D1 DE60315939 D1 DE 60315939D1
Authority
DE
Germany
Prior art keywords
androgen
pharmaceutical composition
composition containing
pharmaceutical
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60315939T
Other languages
English (en)
Other versions
DE60315939T2 (de
Inventor
Robert Gyurik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CPEX Pharmaceuticals Inc
Original Assignee
Bentley Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29251138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60315939(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bentley Pharmaceuticals Inc filed Critical Bentley Pharmaceuticals Inc
Publication of DE60315939D1 publication Critical patent/DE60315939D1/de
Application granted granted Critical
Publication of DE60315939T2 publication Critical patent/DE60315939T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06Anabolic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DE60315939T 2002-04-19 2003-04-21 Pharmazeutische zusammensetzung enthaltend ein androgen Expired - Lifetime DE60315939T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37410302P 2002-04-19 2002-04-19
US374103P 2002-04-19
PCT/US2003/012235 WO2003088974A1 (en) 2002-04-19 2003-04-21 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
DE60315939D1 true DE60315939D1 (de) 2007-10-11
DE60315939T2 DE60315939T2 (de) 2008-05-21

Family

ID=29251138

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60315939T Expired - Lifetime DE60315939T2 (de) 2002-04-19 2003-04-21 Pharmazeutische zusammensetzung enthaltend ein androgen

Country Status (30)

Country Link
US (21) US7320968B2 (de)
EP (2) EP1425019B1 (de)
JP (1) JP2005519985A (de)
KR (2) KR100977896B1 (de)
CN (2) CN102357098B (de)
AR (2) AR039644A1 (de)
AT (1) ATE371456T1 (de)
AU (1) AU2003228612B2 (de)
BR (1) BR0309390A (de)
CA (1) CA2470200C (de)
CY (1) CY1109005T1 (de)
DE (1) DE60315939T2 (de)
DK (1) DK1425019T3 (de)
EA (1) EA009839B1 (de)
EG (1) EG24882A (de)
ES (2) ES2292964T3 (de)
HK (3) HK1082682A1 (de)
IL (1) IL164547A (de)
IS (2) IS2667B (de)
LT (1) LT5235B (de)
LV (1) LV13303B (de)
MX (1) MXPA04010311A (de)
MY (1) MY139721A (de)
NO (1) NO335864B1 (de)
NZ (1) NZ535970A (de)
PL (1) PL213976B1 (de)
SA (1) SA03240158B1 (de)
TW (1) TWI362932B (de)
WO (1) WO2003088974A1 (de)
ZA (1) ZA200408422B (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
US20040072810A1 (en) * 2001-11-07 2004-04-15 Besins International Belgique Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof
MY139721A (en) * 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
US20040259852A1 (en) * 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
US8883769B2 (en) * 2003-06-18 2014-11-11 White Mountain Pharma, Inc. Methods for the treatment of fibromyalgia and chronic fatigue syndrome
BRPI0515040B1 (pt) * 2004-09-09 2021-10-13 Besins Healthcare Luxembourg S.A.R.L Géis de testosterona compreendendo propileno glicol como intensificador de penetração
EP1634583A1 (de) * 2004-09-09 2006-03-15 Laboratoires Besins International Testosterongele enthaltend Propylenglykol als Resorptionsverstärker
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
PL2450041T3 (pl) 2005-10-12 2019-02-28 Unimed Pharmaceuticals, Llc Ulepszony żel zawierający testosteron do zastosowania do leczenia hipogonadyzmu
CN102088956A (zh) * 2008-05-09 2011-06-08 托马有限公司 氯胍用于治疗皮肤/粘膜疾病
CA2726641A1 (en) * 2008-06-05 2009-12-10 Cpex Pharmaceuticals, Inc. Nasal formulations of insulin
US20110097363A1 (en) * 2009-10-22 2011-04-28 Cpex Pharmaceuticals, Inc. Therapeutically Effective Preparations of Insulin
US9642863B2 (en) 2010-11-18 2017-05-09 White Mountain Pharma, Inc. Methods for treating chronic or unresolvable pain and/or increasing the pain threshold in a subject and pharmaceutical compositions for use therein
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
AR086400A1 (es) 2011-05-13 2013-12-11 Trimel Pharmaceuticals Corp Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
KR20230041081A (ko) * 2011-05-15 2023-03-23 에이세러스 바이오파마 인크. 비내용 테스토스테론 바이오-접착제 겔 제형 및 남성의 성선기능저하증을 치료하기 위한 그의 용도
US10568905B2 (en) * 2012-02-14 2020-02-25 Metabolic Therapy Inc. Pharmaceutical composition and method for treating retinal neurodegeneration
KR20150011346A (ko) 2012-04-06 2015-01-30 안타레스 팔마, 인코퍼레이티드 테스토스테론 조성물의 바늘-보조식 젯 주입 투여 장치 및 방법
WO2014047133A1 (en) 2012-09-20 2014-03-27 Gkn Armstrong Whells, Inc. Lock ring spreader
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
US8785426B1 (en) * 2013-12-13 2014-07-22 Upsher-Smith Laboratories, Inc. Testosterone gel compositions and related methods
US20170014417A1 (en) 2015-07-14 2017-01-19 Lipp Life Sciences Llc Pharmaceutical administration system for the transdermal application of vardenafil
WO2019089942A1 (en) * 2017-11-02 2019-05-09 Rick Coulon Formulations for use in the transdermal delivery of proteasome inhibitors
CN112666197B (zh) * 2020-11-29 2022-11-04 山东大学 一种用于tbm的岩渣石英含量测试系统及方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE843140A (fr) * 1975-06-19 1976-10-18 Aazacycloalcan-2-ones 1-substituees et compositions pharmaceutiques contenant ces composes a titre d'excipients
US3989816A (en) * 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4316893A (en) * 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4405616A (en) * 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US3989815A (en) * 1975-06-19 1976-11-02 Nelson Research & Development Company Novel N-bis-azacyclopentan-2-onyl alkanes
US3991203A (en) * 1975-06-19 1976-11-09 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US4423040A (en) * 1980-04-04 1983-12-27 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclohexan-2-ones
US4424210A (en) * 1980-04-04 1984-01-03 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4444762A (en) * 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US4415563A (en) * 1980-04-04 1983-11-15 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclononan-2-ones
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5731303A (en) 1985-12-04 1998-03-24 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery compositions
US5270346A (en) 1986-01-31 1993-12-14 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
US4992422A (en) * 1986-01-31 1991-02-12 Whitby Research, Inc. Compositions comprising 1-substituted azacycloalkanes
US4801586A (en) 1986-04-23 1989-01-31 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agents
US4879275A (en) 1987-09-30 1989-11-07 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agent
US5019395A (en) 1988-03-08 1991-05-28 Warner-Lambert Company Compositions with enhanced penetration
US5676968A (en) * 1991-10-31 1997-10-14 Schering Aktiengesellschaft Transdermal therapeutic systems with crystallization inhibitors
US6190691B1 (en) * 1994-04-12 2001-02-20 Adolor Corporation Methods for treating inflammatory conditions
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
DE19619045C1 (de) 1996-05-02 1997-11-13 Jenapharm Gmbh Verwendung von Kombinationspräparaten zur Behandlung hypogonadaler Männer sowie Männern mit Hypophysenerkrankungen
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6019997A (en) * 1997-01-09 2000-02-01 Minnesota Mining And Manufacturing Hydroalcoholic compositions for transdermal penetration of pharmaceutical agents
DE19701949A1 (de) 1997-01-13 1998-07-16 Jenapharm Gmbh Transdermales therapeutisches System
ES2229473T3 (es) * 1997-01-30 2005-04-16 Novartis Ag Composiciones farmaceuticas sin aceite que contienen ciclosporina a.
DE29704393U1 (de) * 1997-03-11 1997-07-17 Aesculap Ag, 78532 Tuttlingen Vorrichtung zur präoperativen Bestimmung der Positionsdaten von Endoprothesenteilen
US5968919A (en) * 1997-10-16 1999-10-19 Macrochem Corporation Hormone replacement therapy drug formulations for topical application to the skin
NZ504423A (en) * 1997-11-10 2003-04-29 Cellegy Pharma Inc Composition having enhanced penetration capabilities and irritation reducing systems
US6980952B1 (en) * 1998-08-15 2005-12-27 Texas Instruments Incorporated Source normalization training for HMM modeling of speech
EP1031564A1 (de) * 1999-02-26 2000-08-30 Klinge Pharma GmbH Hemmer der Nicotinamidmonononukleotide-Bildung und deren Verwendung zur Krebstherapie
FR2801507B1 (fr) * 1999-11-30 2003-06-27 Pf Medicament Dispositif transdermique auto-adhesif comprenant un reservoir et une matrice contenant le meme principe actif, son procede de preparation et ses utilisations
NZ513964A (en) * 1999-12-08 2004-01-30 Pharmacia Corp Solid-state form of celecoxib having enhanced bioavailability
US6495124B1 (en) 2000-02-14 2002-12-17 Macrochem Corporation Antifungal nail lacquer and method using same
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
AR030312A1 (es) * 2000-08-03 2003-08-20 Antares Pharma Ipl Ag Composicion novedosa para la administracion transdermica y/o transmucosica de compuestos activos, que asegura adecuados niveles terapeuticos
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
KR100861603B1 (ko) 2000-08-30 2008-10-07 유니메드 파마슈티칼스, 엘엘씨 발기부전의 치료 및 남성의 리비도를 증가시키는 방법
DK1322336T3 (da) * 2000-08-30 2013-07-15 Unimed Pharmaceuticals Llc Fremgangsmåde til forøgelse af testosteron og beslægtede steroidkoncentrationer hos kvinder
US6743448B2 (en) 2000-12-11 2004-06-01 Abraham H. Kryger Topical testosterone formulations and associated methods
DE50112206D1 (de) * 2000-12-22 2007-04-26 August Wolff Gmbh & Co Kg Arzn Gelzusammensetzung auf alkoholischer basis zur behandlung von hypogonadismus durch transskrotale applikation
WO2002089849A1 (en) * 2001-05-07 2002-11-14 Corium International Compositions and delivery systems for administration of a local anesthetic agent
US20030027804A1 (en) 2001-06-27 2003-02-06 Van Der Hoop Roland Gerritsen Therapeutic combinations for the treatment of hormone deficiencies
US7169107B2 (en) * 2002-01-25 2007-01-30 Karen Jersey-Willuhn Conductivity reconstruction based on inverse finite element measurements in a tissue monitoring system
AU2003228314C1 (en) 2002-03-15 2009-03-26 Besins Healthcare Luxembourg Sarl Androgen pharmaceutical composition and method for treating depression
MY139721A (en) 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
US20040259784A1 (en) * 2003-06-18 2004-12-23 White Hillary D. Compositions and methods for treatment of muscle pain and muscle wasting

Also Published As

Publication number Publication date
US7608610B2 (en) 2009-10-27
TW200408397A (en) 2004-06-01
WO2003088974A1 (en) 2003-10-30
US20090124590A1 (en) 2009-05-14
US20130059828A1 (en) 2013-03-07
US20140343025A1 (en) 2014-11-20
US7608607B2 (en) 2009-10-27
HK1082682A1 (en) 2006-06-16
CN102357098A (zh) 2012-02-22
HK1167332A1 (en) 2012-11-30
ZA200408422B (en) 2006-06-28
IL164547A (en) 2011-01-31
US20080108590A1 (en) 2008-05-08
EP1425019A4 (de) 2004-11-17
ES2399900T3 (es) 2013-04-04
PL372083A1 (en) 2005-07-11
US8063029B2 (en) 2011-11-22
US20160129016A1 (en) 2016-05-12
PL213976B1 (pl) 2013-05-31
LT2004101A (en) 2005-04-25
TWI362932B (en) 2012-05-01
US20090124589A1 (en) 2009-05-14
US20090131387A1 (en) 2009-05-21
EG24882A (en) 2010-12-01
MXPA04010311A (es) 2005-02-03
US20210308145A1 (en) 2021-10-07
AU2003228612B2 (en) 2006-05-04
US20090192131A1 (en) 2009-07-30
US7935690B2 (en) 2011-05-03
AR087484A2 (es) 2014-03-26
BR0309390A (pt) 2005-02-09
US7608606B2 (en) 2009-10-27
LT5235B (lt) 2005-06-27
IL164547A0 (en) 2005-12-18
HK1098386A1 (en) 2007-07-20
US20100081640A1 (en) 2010-04-01
US7608605B2 (en) 2009-10-27
JP2005519985A (ja) 2005-07-07
NZ535970A (en) 2006-12-22
US20090118252A1 (en) 2009-05-07
CN1662243A (zh) 2005-08-31
US20080275012A1 (en) 2008-11-06
CN1662243B (zh) 2011-10-26
US20210308146A1 (en) 2021-10-07
EA200401410A1 (ru) 2005-04-28
EP1741433A1 (de) 2007-01-10
US20050192260A1 (en) 2005-09-01
ATE371456T1 (de) 2007-09-15
AU2003228612A1 (en) 2003-11-03
KR100952786B1 (ko) 2010-04-14
MY139721A (en) 2009-10-30
LV13303B (en) 2006-08-20
US20080275013A1 (en) 2008-11-06
IS7535A (is) 2004-11-17
KR20090079266A (ko) 2009-07-21
IS2946B (is) 2016-05-15
ES2292964T3 (es) 2008-03-16
NO335864B1 (no) 2015-03-09
IS8870A (is) 2010-01-06
US20090118250A1 (en) 2009-05-07
US7608609B2 (en) 2009-10-27
EP1425019A1 (de) 2004-06-09
US20080103120A1 (en) 2008-05-01
CY1109005T1 (el) 2014-07-02
US20130281416A1 (en) 2013-10-24
AR039644A1 (es) 2005-03-02
CA2470200A1 (en) 2003-10-30
US7320968B2 (en) 2008-01-22
IS2667B (is) 2010-08-15
DK1425019T3 (da) 2008-02-04
EA009839B1 (ru) 2008-04-28
US20150283153A1 (en) 2015-10-08
SA03240158B1 (ar) 2007-02-17
CN102357098B (zh) 2014-12-17
US20090192132A1 (en) 2009-07-30
EP1741433B1 (de) 2012-11-07
KR100977896B1 (ko) 2010-08-24
US7608608B2 (en) 2009-10-27
US8178518B2 (en) 2012-05-15
CA2470200C (en) 2005-07-26
DE60315939T2 (de) 2008-05-21
EP1425019B1 (de) 2007-08-29
NO20045019L (no) 2005-01-14
KR20050011753A (ko) 2005-01-29
US20090118251A1 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
DE60315939D1 (de) Pharmazeutische zusammensetzung enthaltend ein androgen
DE602004017381D1 (de) Zweiteilige selbstklebende Dentalmassen
PT1501534E (pt) Formulacoes farmaceuticas
DK1660104T3 (da) Farmaceutisk formulering indeholdende lanthanforbindelser
ATE380544T1 (de) Umhüllte feste darreichungsform
IS8460A (is) Lyfjafræðileg samsetning sem inniheldur kvetíapín
DE60312049D1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
AU2003291103A8 (en) Pharmaceutical composition
PT1467724E (pt) Composicao farmaceutica orodispersavel de agomelatina
DK1587478T3 (da) Farmaceutisk sammensætning
AU2003250372A8 (en) Pharmaceutical composition
DE60310914D1 (de) Pulverzusammensetzung
ATE477814T1 (de) Stabile faktor-viii enthaltende pharmazeutische zusammensetzung
PT1558263E (pt) Composicao farmaceutica de libertacao prolongada
ATE350016T1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
ATE507831T1 (de) Melatonin enthaltende pharmazeutische formulierung
DE10291905D2 (de) Pharmazeutische Zusammensetzung
DE60217369D1 (de) Pharmazeutische zusammensetzung enthaltend gamma-butyrobetain
IS7581A (is) Lyfjasamsetning
NO20034952D0 (no) Farmasöytiske forbindelser
DE10393889D2 (de) Medikament-Dosimeter-Kombipackung
NO20044164L (no) Farmasoytiske sammensetninger
DE10107261B4 (de) Pharmazeutische Zusammensetzung
ITMI20030705A1 (it) Composizione farmaceutica contenente n-acetil-l-cisteina
DE602004030921D1 (de) Pharmazeutische zusammensetzung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: CPEX PHARMACEUTICALS, INC. (N. D. GES. D. STAA, US

R082 Change of representative

Ref document number: 1425019

Country of ref document: EP

Representative=s name: GRUENECKER, KINKELDEY, STOCKMAIR & SCHWANHAEUSSER,